- Home
- GERN vs IDYA Comparison
GERN vs IDYA Comparison
Compare GERN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- IDYA
- Stock Information
- Founded
- GERN 1990
- IDYA 2015
- Country
- GERN United States
- IDYA United States
- Employees
- GERN N/A
- IDYA N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- IDYA Health Care
- Exchange
- GERN Nasdaq
- IDYA Nasdaq
- Market Cap
- GERN 2.5B
- IDYA 2.6B
- IPO Year
- GERN 1996
- IDYA 2019
- Fundamental
- Price
- GERN $3.66
- IDYA $26.64
- Analyst Decision
- GERN Strong Buy
- IDYA Strong Buy
- Analyst Count
- GERN 10
- IDYA 12
- Target Price
- GERN $6.95
- IDYA $53.08
- AVG Volume (30 Days)
- GERN 9.5M
- IDYA 750.9K
- Earning Date
- GERN 11-07-2024
- IDYA 11-04-2024
- Dividend Yield
- GERN N/A
- IDYA N/A
- EPS Growth
- GERN N/A
- IDYA N/A
- EPS
- GERN N/A
- IDYA N/A
- Revenue
- GERN $29,480,000.00
- IDYA $3,922,000.00
- Revenue This Year
- GERN $30,930.80
- IDYA N/A
- Revenue Next Year
- GERN $315.72
- IDYA $158.10
- P/E Ratio
- GERN N/A
- IDYA N/A
- Revenue Growth
- GERN 9199.68
- IDYA N/A
- 52 Week Low
- GERN $1.64
- IDYA $26.41
- 52 Week High
- GERN $5.34
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- GERN 29.99
- IDYA 33.96
- Support Level
- GERN $3.98
- IDYA $27.52
- Resistance Level
- GERN $4.50
- IDYA $32.67
- Average True Range (ATR)
- GERN 0.21
- IDYA 1.44
- MACD
- GERN -0.05
- IDYA -0.04
- Stochastic Oscillator
- GERN 3.45
- IDYA 3.75
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.